New Immune Modulating Drugs
Posted Mar 23rd 2007 12:43PM by Allie Beatty
Filed under: Type 1, Type 2, Childhood, Adult Onset, Drugs, Research, Products
Just like a referee to normalize play throughout the game - DiaKine Therapeutics is developing ways to normalize the body's immune system.
The new drugs modulate cytokines, part of the body's immune system, which mistakenly attack normal organs and tissue and cause diseases such as: diabetes, multiple sclerosis and inflammatory bowel disease. Research by Dr. Nadler and his collaborators published in 2006 showed that controlling certain cytokines can arrest the progression of, or reverse, type 1 diabetes in an animal model.
The company's first product, IsletLifeLSF Media 1 is designed to improve the viability and insulin producing capabilities of harvested islet cells prior to transplant. This would potentially improve the success rate of the procedure. Additional therapeutics under development by DiaKine include: adjunct therapy to islet cell transplants, halting the progression of type 1 diabetes in newly diagnosed adults, treatment and prevention of Latent Autoimmune Diabetes of Adults (LADA), treatment and prevention of insulin requiring type 2 diabetic, treatment and prevention of diabetes complications.
It all sounds like good stuff in the works. Keep an eye on the progress and press releases of DiaKine, as well as their research partner - the Diabetes Research Institute. A lot is happening these days. What else have you seen or heard about in the autoimmune arena?
Tags: adjunct therapy, AdjunctTherapy, allie beatty, AllieBeatty, arrest the progression of type 1 diabetes, ArrestTheProgressionOfType1Diabetes, c-peptide, C-peptide prevents diabetic complications, C-peptidePreventsDiabeticComplications, cause of diabetes, CauseOfDiabetes, cytokines, diabetes complications, diabetes cure, diabetes investments, diabetes research, diabetes research international, diabetes stocks, diabetes treatment, diabetes type 2, DiabetesComplications, DiabetesCure, DiabetesInvestments, DiabetesResearch, DiabetesResearchInternational, DiabetesStocks, DiabetesTreatment, DiabetesType2, Dr. Nadler, Dr. riccordi, Dr.Nadler, Dr.Riccordi, DRI, Edmonton protocol, EdmontonProtocol, finance.yahoo.com diabetes, Finance.yahoo.comDiabetes, GSK, harvested islet cells, HarvestedIsletCells, healthy organs, healthy tissues, HealthyOrgans, HealthyTissues, immune system, ImmuneSystem, inflammation, inflammatory bowel disease, InflammatoryBowelDisease, insulin dependent diabetes, InsulinDependentDiabetes, islet transplants, IsletLifeLSF, islets, IsletTransplants, LADA, Latent Autoimmune Diabetes, LatentAutoimmuneDiabetes, LLY, LoveDiabetes, mistakenly attack, MistakenlyAttack, modulate cytokines, ModulateCytokines, multiple sclerosis, MultipleSclerosis, normalize the body’s immune system, NormalizeTheBody’sImmuneSystem, PFE, preventing diabetes complications, PreventingDiabetesComplications, reverse type 1 diabetes, ReverseType1Diabetes, Shop4Cures, tampa, fl, Tampa,Fl, type 2 diabetes, Type2Diabetes, universiity of tampa, UniversiityOfTampa, xenotransplantation
1. This is all very good and optimistic news for newly acquired T1DM or MS, but what about those of us who already have either disease and all we have going at this time is what is referred to as "Management"?
Posted at 9:58PM on Mar 23rd 2007 by BetterCell